Moncef Slaoui resigned from Moderna’s board of directors when the Trump administration tapped him last week to be chief advisor for its Operation Warp Speed, a push to develop and distribute a vaccine to address the COVID-19 pandemic. But he still had stock options for about 156,000 Moderna shares; based on Friday’s closing price, they were worth about $10 million.
Moderna is among the companies developing a potential vaccine for the virus, and in April the federal government agreed to award it up to $483 million to speed up that process. Continue reading.